JP2005530696A5 - - Google Patents

Download PDF

Info

Publication number
JP2005530696A5
JP2005530696A5 JP2003570852A JP2003570852A JP2005530696A5 JP 2005530696 A5 JP2005530696 A5 JP 2005530696A5 JP 2003570852 A JP2003570852 A JP 2003570852A JP 2003570852 A JP2003570852 A JP 2003570852A JP 2005530696 A5 JP2005530696 A5 JP 2005530696A5
Authority
JP
Japan
Prior art keywords
kit
testing
concentration
less
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003570852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/001071 external-priority patent/WO2003072106A2/en
Publication of JP2005530696A publication Critical patent/JP2005530696A/ja
Publication of JP2005530696A5 publication Critical patent/JP2005530696A5/ja
Withdrawn legal-status Critical Current

Links

JP2003570852A 2002-02-27 2003-02-26 物質使用障害を治療するためのチロシンキナーゼ阻害剤の使用方法 Withdrawn JP2005530696A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35965102P 2002-02-27 2002-02-27
PCT/IB2003/001071 WO2003072106A2 (en) 2002-02-27 2003-02-26 Use of tyrosine kinase inhibitors for treating substance use disorders

Publications (2)

Publication Number Publication Date
JP2005530696A JP2005530696A (ja) 2005-10-13
JP2005530696A5 true JP2005530696A5 (https=) 2006-03-09

Family

ID=27766119

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003570852A Withdrawn JP2005530696A (ja) 2002-02-27 2003-02-26 物質使用障害を治療するためのチロシンキナーゼ阻害剤の使用方法

Country Status (9)

Country Link
US (1) US20050203098A1 (https=)
EP (1) EP1490067B1 (https=)
JP (1) JP2005530696A (https=)
AT (1) ATE408407T1 (https=)
AU (1) AU2003209933A1 (https=)
CA (1) CA2477726A1 (https=)
DE (1) DE60323613D1 (https=)
ES (1) ES2314223T3 (https=)
WO (1) WO2003072106A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
KR20030048026A (ko) 2001-07-06 2003-06-18 펜웨스트 파머슈티칼즈 컴파니 옥시모르폰의 서방형 제제
CN1610551A (zh) 2001-07-06 2005-04-27 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的肠胃外给药
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
NZ578944A (en) 2007-02-13 2011-03-31 Ab Science PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS
CN105974131B (zh) * 2016-06-16 2017-12-26 武汉大学 c‑Kit作为药物成瘾治疗靶点的应用
US20220079950A1 (en) * 2018-12-31 2022-03-17 The Regents Of The University Of California Therapeutic combinations as antidotes for organophosphate exposure
CN112575073B (zh) * 2019-09-30 2022-10-04 武汉大学 c-Kit作为成瘾诊断及监测标志物的应用
CN112569238A (zh) * 2019-09-30 2021-03-30 武汉大学 伊马替尼及其衍生物与镇痛药联合用药或复方制剂在治疗疼痛中的应用
EP4203942B1 (en) * 2020-08-28 2026-04-15 Emory University Ibrutinib for use in treating cocaine use disorder and related conditions
CN114573591B (zh) * 2022-04-16 2023-04-25 成都施贝康生物医药科技有限公司 一种取代的吡咯并嘧啶化合物及其应用
CN117461602B (zh) * 2023-10-25 2024-10-25 六合熙诚(北京)信息科技有限公司 一种吗啡成瘾动物模型的构建方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (https=) * 1992-04-03 1994-06-21 Ciba Geigy Ag

Similar Documents

Publication Publication Date Title
JP2005530696A5 (https=)
DE602004021927D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
DE60313602D1 (de) N-iPHENYL(PIPERIDIN-2-YL)METHYLöBENZAMIDDERIVATE,VERFAHREN ZU IHRER HERSTELLUNG UND IHRE THERAPEUTISCHE ANWENDUNG
ATE554113T1 (de) Butencopolymere und verfahren zu ihrer herstellung
ATE541843T1 (de) 2-acylamino-4-phenylthiazolderivate, ihre herstellung und anwendung als chemokin antagonisten
ATE489469T1 (de) Maize kompositionen mit erhöhtem lysine gehalt und methoden zu deren detektion
DE502004011957D1 (de) Neue cyanopyrrolidide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ITPD20020138A0 (it) Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
AU2003900863A0 (en) Inertial and radiolocation method
DE602004024758D1 (de) Polyimidzusammensetzungen mit Widerstand gegen Wassersorption, und Verfahren hierzu
JP2005526058A5 (https=)
EP1765327A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
DE502004002403D1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
JP2005515295A5 (https=)
DE60335812D1 (de) Biosensor und verfahren zu seiner herstellung
ITMO20030289A1 (it) Apparati, metodo e articolo.
NL1029360A1 (nl) Gesubstitueerde heteroaryl- en fenylsulfamoylverbindingen.
ATE482193T1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
DE50209101D1 (de) Hitzebeständige filterlage, filterkörper und verfahren zu seiner herstellung
ATE473738T1 (de) 1-sulfonylindolderivate, verfahren zu ihrer herstellung und ihre verwendung als 5-ht6 liganden
DE60332463D1 (de) Hochbrillianter mechanolumineszenzstoff und verfahren zu seiner herstellung
DE60239493D1 (de) Halbleiterbauelement und verfahren zu seiner herstellung
IS8212A (is) Nýjar 8-aza-bísýkló[3.2.1]oktanafleiður og notkunþeirra sem mónóamín-taugaboðefnaendurupptökuhindrar
WO2006070023A3 (en) Method for reversing multiple resistance in animal cells
NO20033998L (no) Fremgangsmate for a bestemme resistivitetsindeksen, som en funksjon av vannmetning, til sten med kompleks porositet